Nephramin Injection

Adult administration

Generally, administer intravenously by dripping 250–500 mL per day (1.6–3.2 g of nitrogen and 13.4–26.8 g of essential amino acids). If calorie sources are administered simultaneously, use this drug mixed aseptically with 500 mL of 70% glucose in 250 mL of this drug (this drug is diluted to 1.8%, with 47% glucose). The usual administration rate for the first dose is 20–30 mL per hour, increasing by 10 mL per hour up to a maximum of 60–100 mL every 24 hours.

Child administration

For children, the initial total amount per day should be small, and it should be gradually increased, ensuring that no more than 1 g of essential amino acids per day per kg of body weight is administered.

This medication must only be used according to a physician's instructions. It should not be used in patients with hepatic coma, severe electrolyte imbalance, reduced circulating blood volume, hyperammonemia, congenital amino acid metabolism disorders, symptomatic heart failure, and patients with fluid overload. Caution should be exercised when administering to patients with congestive heart failure, children, low birth weight infants, and patients with gastrointestinal bleeding, as allergic reactions or asthma attacks may occur due to the sodium bisulfite component. During administration, adverse reactions such as general itching, rash, nausea, vomiting, and palpitations may occur, so administration should be immediately stopped if any symptoms appear. Rapid administration of large amounts may lead to acidosis, and regular monitoring of liver function tests and blood urea and ammonia levels is necessary. This drug is mainly used to assist protein metabolism and is suitable for patients who are unable to take oral intake or for those on dialysis. Careful observation of hydration and electrolyte status is required during administration, and diabetic patients should pay attention to blood sugar control. Mixing this drug with other medications may be hazardous, so it must be administered according to an expert's instructions, and it is important to use it immediately after mixing. In the case of overdose, side effects or edema may occur, necessitating the reduction or cessation of administration. Since this drug contains electrolytes, care should be taken with electrolyte balance in the event of large volumes being administered, and it should be administered slowly intravenously to reduce side effects. To minimize the risk of infection during administration, sterility must be maintained, and solutions that are discolored or contaminated should not be used. Until the packaging is opened, care should be taken to prevent the solution from deteriorating, and any remaining solution after use should not be reused.

Serious side effects

Urticaria, severe swelling (edema), chest tightness, difficulty breathing, asthma attacks, severe allergic reactions, consciousness disorders due to hyperammonemia, respiratory problems

Mild side effects

• General itching
• rash
• urticaria
• nausea
• vomiting
• loss of appetite
• chest discomfort
• palpitations
• acidosis
• elevated AST/ALT

This drug should be stored in a tightly sealed container to prevent air from entering, and the storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. By storing it this way, the effectiveness of the drug can be well maintained.

Appearance

This drug is a colorless to pale yellow transparent injection in a polypropylene aqueous injection container.

Package unit

250mL/bag